Irubis GmbH. (8/14/25). "Press Release: Irubis Appoints Matthias Eggers as New CEO to Lead USA Expansion and Commercial Scale-Up". Munich.

	Organisation	Irubis GmbH
	Organisation 2	Beckman Coulter Inc., Life Science Division (Beckman Coulter Life Sciences)
	Today	Beckman Coulter Life Sciences
	Group	Danaher (Group)
	Product	Monipa real-time monitoring system (mid infrared spectroscopy-based system for biopharma process analytical technology)
	Product 2	BIOTECH
	Index term 2	m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences
	Person	Eggers, Matthias (Irubis 202508– CEO before Genepoint + m2p-labs + Thermo Fisher + Resistell AG)
	Person 2	Müller, Anja (Irubis –202508 CEO before COO + Co-Founder STEPPED DOWN 8/25)

IRUBIS GmbH, a life science tools startup pioneering innovation in real-time bioprocess analytics, today announced the appointment of Matthias Eggers as Chief Executive Officer. Matthias succeeds Anja Müller, former CEO of IRUBIS, who has decided, after careful consideration and for private reasons, to step back from the role at IRUBIS.

We respect her decision and appreciate the leadership and value she brought to the organization. During her tenure, she played a pivotal role in the growth of IRUBIS, shaping and executing strategy, winning over investors and partners, and laying the foundation for the company’s growth. Her strategic mindset and unwavering dedication have a lasting impact on the organization and all those who had the pleasure of working with her.

To continue IRUBIS' trajectory of success, the IRUBIS Advisory Board and management team have decided to appoint a new CEO with deep industry expertise and a strong focus on the USA commercialization. This leader will spearhead the ongoing market adoption of IRUBIS’ unique analytical technology while supporting our vision for growth and strategic expansion. As we turn the page, IRUBIS enters a new phase focused on commercial expansion, international growth, and market leadership in Process Analytical Technology (PAT) for bioprocessing. Matthias Eggers brings over 15 years of global leadership experience in scaling bioprocessing technologies. Prior to joining IRUBIS, he led commercial strategy at m2p-labs, where he grew revenue multiple times, built international sales teams, and successfully guided the company through acquisition and integration into Beckman Coulter Life Sciences. His experience includes executive roles at Thermo Fisher Scientific, Resistell AG, and most recently, Genepoint in Shanghai.

“Matthias is an exceptional commercial leader with a proven track record in scaling bioprocess technology companies,” said Dr. Karl Rix, Chair of the Advisory Board. “We are happy to have him on board. Under Matthias' leadership, we expect IRUBIS to enter its next growth phase — bringing
Monipa to more partners globally and leading our strategic expansion into the USA market.”

As CEO, Matthias will lead the company’s operations and accelerate international go-to-market efforts, with a focus on building further strategic partnerships across Europe and the USA and overseeing the expansion of IRUBIS' commercial infrastructure to the USA.

“IRUBIS has built an outstanding platform with Monipa,” said Matthias Eggers. “The team has created something genuinely disruptive in inline, real-time bioprocess analytics. I’m excited to build on this foundation and scale the business to meet the growing global demand for smart, efficient
process control in biomanufacturing.”

The appointment marks a key milestone in IRUBIS’ continued growth and its commitment to enabling smarter, faster, and more scalable bioprocessing with intuitive, real-time PAT tools.

About IRUBIS

IRUBIS was founded in September 2017 by Lorenz Sykora-Mirle, Alexander Geißler, and Anja Müller with the goal of bringing life-saving biopharmaceutical drugs to patients faster. The company develops advanced PAT tool based on mid-infrared spectroscopy to bring intelligence to biopharmaceutical manufacturing. Its flagship product, Monipa, with single-use capabilities delivers inline, real-time concentration data for proteins, excipients, and nucleic acids—empowering faster decision-making, reducing batch loss, and simplifying bioprocess development and scale-up.

For media inquiries or interview requests:
press@irubis.com
www.irubis.com

Record changed: 2025-10-15